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Abstract
Background: The identification of early mechanisms underlying Alzheimer’s Disease (AD) and associated biomarkers could
advance development of new therapies and improve monitoring and predicting of AD progression. Mitochondrial
dysfunction has been suggested to underlie AD pathophysiology, however, no comprehensive study exists that evaluates
the effect of different familial AD (FAD) mutations on mitochondrial function, dynamics, and brain energetics.
Methods and Findings: We characterized early mitochondrial dysfunction and metabolomic signatures of energetic stress
in three commonly used transgenic mouse models of FAD. Assessment of mitochondrial motility, distribution, dynamics,
morphology, and metabolomic profiling revealed the specific effect of each FAD mutation on the development of
mitochondrial stress and dysfunction. Inhibition of mitochondrial trafficking was characteristic for embryonic neurons from
mice expressing mutant human presenilin 1, PS1(M146L) and the double mutation of human amyloid precursor protein
APP(Tg2576) and PS1(M146L) contributing to the increased susceptibility of neurons to excitotoxic cell death. Significant
changes in mitochondrial morphology were detected in APP and APP/PS1 mice. All three FAD models demonstrated a loss
of the integrity of synaptic mitochondria and energy production. Metabolomic profiling revealed mutation-specific changes
in the levels of metabolites reflecting altered energy metabolism and mitochondrial dysfunction in brains of FAD mice.
Metabolic biomarkers adequately reflected gender differences similar to that reported for AD patients and correlated well
with the biomarkers currently used for diagnosis in humans.
Conclusions: Mutation-specific alterations in mitochondrial dynamics, morphology and function in FAD mice occurred prior
to the onset of memory and neurological phenotype and before the formation of amyloid deposits. Metabolomic signatures
of mitochondrial stress and altered energy metabolism indicated alterations in nucleotide, Krebs cycle, energy transfer,
carbohydrate, neurotransmitter, and amino acid metabolic pathways. Mitochondrial dysfunction, therefore, is an underlying
event in AD progression, and FAD mouse models provide valuable tools to study early molecular mechanisms implicated in
AD.
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Introduction
Alzheimer’s Disease (AD) is a devastating neurodegenerative
disorder characterized by progressive memory loss and impair-
ment in behavior, language, and visuospatial skills [1]. The
familial form of AD (FAD) has an early-onset and is caused by
mutations in the amyloid precursor protein (APP) and presenilin 1
and 2 (PS1 and PS2) genes that lead to the accumulation of Ab
peptide [2]. Recent data suggest Ab directly affects mitochondria
early in AD contributing to the loss of synaptic function and
plasticity, which are increasingly recognized as major mechanisms
responsible for memory loss in AD [3]. Indeed, a decrease in
cytochrome oxidase activity and energy metabolism and an
increase in free radical production were detected in AD patients
and AD mice prior to the formation of amyloid plaques and
memory loss [4–7]. In neurons from AD mice, Ab associates with
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32737mitochondrial membranes altering their trafficking, function and
dynamics with synaptic mitochondria being particularly suscepti-
ble to Ab-induced damage [8–12].
Mitochondria are dynamic organelles that actively move within
the axons to ensure adequate energy supply. In the cell body,
mitochondrial movement is essential for proper calcium buffering
and energy transfer and distribution [13–16]. Therefore, it is not
surprising that altered dynamics could be a causative factor in
mitochondrial failure. However, the evaluation of the effect of
particular FAD mutations on the development of mitochondrial
dysfunction has not been done. Gaining such knowledge is
important in order to identify the best animal models that most
closely mimic human disease to reveal molecular mechanisms of
mitochondrial dysfunction in AD, to develop the efficient tools for
early diagnosis, and for the evaluation of the novel therapeutic
approaches.
In the present study, we utilized three FAD transgenic mouse
models, APP, PS1, and APP/PS1. In order to evaluate the impact
of the particular mutation on mitochondrial dynamics and
function, we examined organelle motility, distribution, ultrastruc-
ture and function in neurons and brain tissue of FAD mice starting
from embryonic day 17 till the age when the onset of memory and
the development of amyloid deposits become prominent for each
particular mouse model. Thus, axonal trafficking was examined in
embryonic neurons (E17); mitochondrial distribution and ultra-
structure was evaluated in neurons (E17) and brain tissue of FAD
mice 8, 12 and 40 weeks of age; brain function and metabolomic
profiling was done in brain tissue from 16, 28 and 36 weeks
old animals. We found that in all these mice mitochondrial
dysfunction preceded the onset of memory phenotype and the
formation of amyloid plaques, however, the development of
mitochondrial abnormalities was mutation specific. Inhibition
of axonal trafficking was the earliest dysfunction detected in
embryonic neurons from PS1 and APP/PS1 mice. Loss of
morphology was most prominent in APP and APP/PS1 mice.
Application of metabolomic profiling allowed identifying metab-
olites and metabolic pathways that were affected in all three FAD
mouse models, along with specific metabolomic signatures of
mitochondrial stress associated with particular FAD mutation.
Metabolic biomarkers adequately reflected gender differences
similar to that reported for AD patients and correlated well with
the biomarkers currently used for diagnosis in humans. Our data
validate the use of FAD mice as a tool to study mitochondrial
dysfunction, which underlies the development of AD in multiple
FAD mouse models regardless of the origin of mutation and is
accompanied by specific metabolic changes useful for early
diagnosis and monitoring the disease progression.
Results
Trafficking of mitochondria is inhibited in hippocampal
neurons from PS1 and APP/PS1 mice
Altered mitochondrial motility, distribution and dynamics were
shown to contribute to the development of AD in animal models
and in humans [8,17–22]. However, it is not clear whether
different FAD mutations affect mitochondrial dynamics and
function to the same extent and within the same time frame
relevant to the development of AD. To determine the effect of
FAD mutations on mitochondrial motility, we investigated axonal
trafficking of mitochondria in primary hippocampal (Hip) and
cortical (Ctx) neurons from three FAD transgenic mouse models.
The first model includes mice that over-express mutant human
APP gene. These mice are characterized by the presence of high
levels of soluble Ab by 6 months of age, and fibrillar plaque
deposition and behavioral deficits that appear between 9 and 11
months of age [23–25]. The second model, where mice express
mutant human PS1 (M146L), is characterized by increased levels
of murine Ab42. However, these mice do not form amyloid
plaques and do not demonstrate cognitive impairment till at least
12 months of age [26,27]. Transgenic mice from the third model
express both mutant human APP and PS1 (APP/PS1) [28]. These
mice have accelerated AD phenotype characterized by amyloid
deposits and behavioral deficits in as little as 13–16 weeks [28]. We
have examined axonal trafficking of mitochondria in live
embryonic neurons from APP, PS1 and APP/PS1 mice, and
compared it to control animals utilizing real time imaging [29].
Non-transgenic (NTG) littermates obtained from the crosses
between APP and PS1 mice were used as controls similar to the
previous study [28]. Mitochondria in neurons were visualized
using the specific dye tetramethylrhodamine methyl ester
(TMRM) that does not affect organelle motility [29] (Figure 1
A–C, Movie S1). For each neuronal genotype, we estimated rates
of mitochondrial movement in anterograde (from the cell body)
and retrograde (to the cell body) directions, distance each
mitochondrion traveled between stops, the percent of stationary
mitochondria, average mitochondrial length, and number of
organelles per axonal length (Figure 1D–I).
We have found that FAD mutations have markedly different
effects on mitochondrial dynamics. Thus, movement of mitochon-
driainPS1 and APP/PS1 neuronswas significantlyinhibitedinboth
anterograde and retrograde directions comparing to NTG litter-
mates. Anterograde motility in NTG neurons (0.9360.55 mm/sec)
was reduced in PS1 (0.6860.33 mm/sec, p,0.001) and APP/PS1
neurons (0.4960.29 mm/sec, p,0.001) (Figure 1F). Similarly,
mitochondrial movement in retrograde directions changed from
0.9760.63 mm/sec in NTG neurons to 0.7160.33 mm/sec in PS1
(p,0.001) and 0.4160.63 mm/sec in APP/PS1 neurons (p,0.001)
(Figure 1G). Movement of mitochondria in APP/PS1 neurons was
affected to a greater extent than in singly transgenic PS1 mice
(Figure 1 F,G, p,0.05). However, trafficking of mitochondria in
neurons from APP mice was not affected and neither the velocities
nor thepattern of motiondiffer fromNTG neurons(Figure 1D,F,G).
Remarkably, mitochondria in PS1 neurons not only moved slowly
but also tended to cover significantly shorter distances between stops
(Figure 1D). Thus, 80% of mitochondria in PS1 neurons covered
distances smaller than 2 mm comparing to 40% in NTG, APP and
APP/PS1 neurons, and almost none of the organelles in the PS1
neurons covered distances greater than 5 mmi nb o t hd i r e c t i o n s
(Figure 1D). Despite stronger inhibition of trafficking in APP/PS1
neurons compared to PS1 cells (Figure 1F,G), the distances covered
by mitochondria in APP/PS1 neurons did not differ from NTG or
APP cells (Figure 1D). We also analyzed the amount of stops per
distance and determined that mitochondria in PS1 and APP/PS1
cells stopped more often. Thus, the ratio of stops per distance was
0.23 and 0.27 in NTG and APP neurons, respectively. However, in
PS1 and APP/PS1 neurons, this number was significantly higher
and reached 0.45 and 1.17, respectively. Along with reduced
motility, mitochondria in PS1 and APP/PS1 neurons became
progressively immobilized. In neurons from NTG and APP mice 58
to 60% of organelles was stationary. In PS1 and APP/PS1 neurons,
the percent of immobilized mitochondria increased to 85 and 92,
respectively (p,0.01). Analysis of mitochondrial length and
distribution in axons of embryonic neurons revealed significant
reduction inthe number oforganelles per axonallength inAPP/PS1
neurons comparing to NTG,PS1 and APPcells (p,0.01) (Figure 1I).
Mitochondria were significantly shorter in neurons from APP
(1.7161.17 mm, p,0.001) and PS1 (1.2460.69 mm, p,0.0001)
neurons compared to NTG (2.1561.13 mm) and APP/PS1
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length was significantly increased compared to NTG and APP/PS1
neurons (Figure 1I). Thus, our data suggest that mitochondrial
trafficking and distribution are altered in embryonic neurons from
FAD mice. Individual FAD mutations differentially affect mito-
chondrial dynamics thus suggesting distinct mechanisms. Synergis-
Figure 1. Mitochondrial trafficking and distribution in primary embryonic neurons from APP, PS1 and APP/PS1 mice. A–C. Real time
imaging of mitochondrial movement within the axon of Hip neuron from PS1 mouse 7 days in culture. A. Phase image of the axon; cell body is in the
upper right corner. B. Same axon with mitochondria visualized using TMRM. Scale bar, 10 mm. C (a–c). Recording of mitochondrial movement in live
axon: arrow and circle indicate the progress of the same organelle along the axon with time. Images were acquired using LSM 510 laser scanning
microscope (Carl Zeiss) with 1006oil DIC (1.4 na) lens. Scale bar, 5 mm. D. Mitochondria in PS1 neurons cover significantly shorter distances between
stops in both, anterograde and retrograde directions compared to organelles in NTG, APP or APP/PS1 neurons. Almost no mitochondria in PS1
neurons cover distances longer than 10 mm. Number of organelles taken into analysis is the same as in (F,G). Blue – NTG; Red – APP; Orange – APP/
PS1; Green – PS1. *p,0.001. E. Selective analysis of mitochondrial dynamics was done using analytical software (Analyze) that allows to trace each
organelle from the first frame (a) through all 600 frames of the movie (stacked movie frames, b) to generate a final profile of movement (c). Resultant
kymograph (c) is used to calculate velocities and identify the number of stationary and moving mitochondria. Rates of organelle motility in
anterograde (F) and retrograde (G) directions include analysis of movement of 74 to 285 individual mitochondria in 24 to 33 neurons from at least
three individual platings for each genotype. *, p,0.001; **, p,0.05. H. Length of 85–156 individual mitochondrion was estimated in five randomly
selected axons in E17 neurons. *, p,0.001; **, p,0.0001. I. The number of organelles normalized per axonal length in embryonic neurons from NTG
and AD mice used in axonal trafficking analysis. Number of mitochondria increases in APP and PS1 mice, and decreases in APP/PS1 cells comparing to
NTG neurons. *, p,0.01. Colors as in D.
doi:10.1371/journal.pone.0032737.g001
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explain the stronger phenotype observed in APP/PS1 neurons
comparing to PS1.
Inhibition of mitochondrial trafficking in PS1 and
APP/PS1 mice does not correlate with Ab levels
We next determined whether differences observed in the extent
of mitochondrial trafficking inhibition in FAD mice depended on
the levels of Ab. Estimation of Ab levels in the brain tissue of the
newborn mice has not been done before. To specifically compare
levels of Ab in the Ctx and Hip tissue of the FAD newborn mice,
we applied a well-established immunohistochemistry technique
[25] using a panel of anti-Ab antibodies (Figure 2). Detection with
a 4G8 monoclonal antibody that recognizes both, murine and
human abnormally processed Ab isoforms along with the
precursor forms of Ab revealed lack of plaques in any FAD
mouse brains examined (Figure 2 a–d). Levels of Ab in the CA1
region of the Hip were very low in PS1 mice compared to APP
and APP/PS1 animals (Figure 2A, f–h). Levels of Ab in CA1
region in APP/PS1 mice were dramatically increased compared to
APP mice (Figure 2A, g, h). Similar increase in Ab levels in APP/
PS1 mice compared to APP was observed using 6E10 antibody
that recognizes only human Ab (data not shown). Moreover,
application of polyclonal A11 antibody that specifically recognizes
murine and human Ab oligomers revealed abundant presence of
these species in all three FAD mouse brains (Figure 2A, i–l). The
densitometry measurements confirmed the increase of Ab levels in
APP and APP/PS1 mice specifically in the Hip as measured with
4G8 antibody (Figure 2B). The increase in the levels of Ab
oligomers was significant in both Ctx and Hip regions in PS1, APP
and APP/PS1 mice (Figure 2 B). The lack of correlation between
the extent of trafficking inhibition and levels of Ab in PS1 and
APP/PS1 mice suggests different mechanisms.
Inhibition of axonal trafficking is a general defect that
occurs in all three FAD mouse models and is not specific
for mitochondria
We next examined whether inhibition of axonal trafficking in
FAD mice was specific for mitochondria. Using the same movies
that were generated to study mitochondrial motility, we analyzed
Figure 2. Levels of Ab in brain tissue of 1-day-old APP, PS1, APP/PS1 and NTG mice. A. Levels of Ab in brain tissue were determined using
monoclonal antibody 4G8 that recognizes human and mouse abnormally processed Ab isoforms and precursor forms (a–d). Scale bar, 200 mm. Levels of
AbinCA1 Hippyramidalneuronsdetectedwith4G8antibody (e–h) or antibodyA11thatrecognizes Aboligomers(i–l).Scalebar,20 mm. B.Densitometry
measurements of immunostaining produced by 4G8 and A11 antibodies in a–l. The lighter staining of the NTG brain resulted in ratios closer to 1,
indicating the stained tissue was almost as bright as the bare slide and therefore, had lower Ab immunoreactivity. As the Ab immunoreactivity increases,
the normalized intensity ratios decrease, with the lowest values observed in the APP/PS1 mouse brain because the tissue becomes darker and closer to
black. Data is expressed as mean 6 SEM. Blue – Ctx 4G8; red – Hip 4G8; green – Ctx A11; purple – Hip A11. * ,0.01. Ab – antibody.
doi:10.1371/journal.pone.0032737.g002
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stained with the mitochondrial marker TMRM and which motility
was traceable in the bright field recording (Figure 3A, ‘‘e’’). Based
on their size and appearance, these vesicles most likely are
endosomes or lysosomes [29]. Similar to the results obtained for
mitochondrial movement, we have determined that round vesicles
moved slower in both anterograde and retrograde directions
(Figure 3B), covered shorter distances between stops (Figure 3C),
and stopped more frequently in neurons from PS1 and APP/PS1
mice (Figure 3D). However, contrary to the movement of
mitochondria, specific and significant inhibition of retrograde
transport of round vesicles was also observed in neurons from
APP mice (Figure 3B). Thus, rates of retrograde transport in APP
neurons (0.6860.31 mm/s) were significantly reduced comparing to
the rates in NTG neurons (0.9860.23 mm/s, p,0.001). Vesicles in
APP neurons also covered shorter distances comparing to NTG
neurons. In NTG cells, 42% and 55% of vesicles covered distances
longer than 4 mm in retrograde and anterograde directions,
respectively (Figure 3C). However, in APP neurons, the number
of vesicles that cover distances over 4 mm dropped to 24 and 32%,
respectively (p,0.01). In PS1 and APP/PS1 cells, the number of
vesicles that cover 4 mm was reduced to 10% (Figure 3C). The ratio
between stops per distance was significantly increased in PS1 (0.63,
p,0.001) and APP/PS1 (0.95, p,0.001) neurons compared to
NTG (0.22) or APP (0.27) neurons (Figure 3D). Our data suggest
inhibition of axonal trafficking in embryonic PS1, APP and APP/
PS1 neurons is a general defect that affects movement of multiple
vesicles and organelles.
Neurons with inhibited mitochondrial trafficking are
more susceptible to excitotoxic cell death
Besides energy production, regulation of intracellular calcium is
another main function of mitochondria. Mitochondrial motility
and positioning in neurons is essential for proper calcium buffering
[13–15]. Since we found that axonal trafficking of mitochondria
was significantly altered in neurons from APP/PS1 and PS1 mice,
we investigated whether these cells exhibit increased sensitivity to
calcium entry caused by stimulation of NMDA receptors.
Figure 3. Inhibition of axonal trafficking in neurons from PS1 and APP/PS1 mice is not specific to mitochondria. A. Analysis of real
time movement of round-shaped vesicles (endosomes or lysosomes, ‘‘v’’) that were not stained with TMRM was done using same movies that were
acquired to study mitochondrial (‘m’) trafficking. Scale bar, 4 mm. B. Similar to mitochondria, round-shaped vesicles move with reduced velocities in
both, anterograde and retrograde directions, travel shorter distances between stops in neurons from APP, PS1 and APP/PS1 mice (C), and stop more
frequently in neurons from PS1 and APP/PS1 mice (D). Analysis was done in randomly selected neurons (13–19 for every genotype); pattern and rate
of motion of 10 to 58 individual vesicles was analyzed. *p,0.001.
doi:10.1371/journal.pone.0032737.g003
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excitotoxic cell death in neurons from all three FAD mouse models
that correlated with the extent of mitochondrial trafficking
inhibition (Figure 4A). Treatment with 80 mM of NMDA caused
25% loss of neurons from NTG and 30% from APP mice
(Figure 4A, open circles and squares). However, neurons from
PS1 and APP/PS1 demonstrated 45% and 50% cell loss,
respectively (Figure 4A, closed circles and triangles). The response
to the lower doses of NMDA was also more robust in APP/PS1 and
PS1 neurons compared to NTG or APP neurons (Figure 4A, doses
below 10 mM). Our data suggest that neurons with inhibited
mitochondrial motility become susceptible to excitotoxic cell death.
Alterations in mitochondrial morphology and localization
in FAD mice precede the onset of memory deficit and
formation of amyloid plaques
Mitochondrial distribution is essential for maintaining synaptic
function and transmission [20,30]. Mislocalization of mitochondria
induced by Ab42 in Drosophila was sufficient to cause late-onset
Figure 4. Mitochondrial distribution is altered in hippocampus of AD mice. A. Neurons in APP/PS1 and PS1 mice exhibit increased
sensitivity to NMDA treatment. Open circles – NTG; Open squares – APP; Close circles – APP/PS1; Triangles – PS1. B. Electron micrographs of an
altered mitochondrial distribution in brain of APP/PS1 mouse 8 weeks old compared to NTG mouse of the same age. Asterisk denotes mitochondria
with altered shape; arrowheads denote accumulation of mitochondria in neuropils. Scale bar, 5 mm (APP/PS1), 2 mm (NTG). C. Accumulation of
normal and degenerating (asterisks) mitochondria in brain of APP mouse 12 weeks old. Scale bar, 500 nm.
doi:10.1371/journal.pone.0032737.g004
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impairment in AD transgenic mice has been linked to the extent
of synaptic mitochondrial dysfunction [32]. Therefore, we exam-
ined whether synaptic and non-synaptic mitochondrial structure,
integrity and distribution were altered in Hip tissue of APP, PS1,
and APP/PS1 mice 8, 12, 24, 30 and 40 weeks of age using electron
microscopy (EM). Wehavefound thatMito distributionwasalready
altered in neuropils in all three FAD mice between 8 and 12 weeks
of age (Table 1). ‘‘Piling’’ of mitochondria in neuropils in APP/PS1
mice and trafficking ‘‘jams’’ consisted of normal and degenerating
mitochondriawereobserved inbraintissue from allthreeFADmice
(Figure 4B, C). However, quantification of mitochondrial distribu-
tion revealed a reduction in the number of mitochondria per
neuropil or per the length of neuropil in all three FAD mice starting
at8–12weeksofage and persistinginAPP/PS1micetill40weeksof
age (Table 1). Neuropils from PS1 and APP/PS1 mice had the most
pronounced reductioninthe numberoforganellesat12weeks.This
is consistent with our observations that the number of Mito was
significantly reduced in the embryonic APP/PS1 neurons suggest-
ing that altered mitochondrial distribution in these mice is
associated with the early stages of AD progression (Figure 1F).
Interestingly, mitochondrial length was significantly increased in the
brains of FAD mice with reduced number of mitochondria per
neuropil (Table 1, Figure 5A–C).
Table 1. Mitochondrial distribution and structural characteristics in brain tissue from NTG, APP, PS1, and APP/PS1 mice based on
electron microscopy examination.
Genotype
Age,
weeks
# of
Neuropils
Neuropil
length, mm
# of
Mito
Mito per
neuropil
Mito per
neuropil length
Mito
length, mm
Abnormal
Mito, %
NTG 8 83 290.5 143 1.7 0.49 1.1160.96 0
12 14 150.6 53 3.8 0.35 2.1160.89 0
40 25 239.6 62 2.5 0.26 2.3161.05 4
APP 8 29 405.3 58 2.0 0.14* 2.0361.71* 3
12 16 151.9 48 3.0 0.32 2.8561.72 5
40 21 158.5 39 1.9 0.25 2.0161.65 20
PS1 8 35 200.9 74 2.1 0.37 1.2761.01 2
12 21 231.6 40 1.9 0.17* 4.0663.12** 1
40 15 133.4 44 2.9 0.33 2.3261.42 5
APP/PS1 8 60 407.2 114 1.9 0.28* 1.2360.98 1
12 23 180.4 41 1.8 0.23* 2.8561.42* 7
40 23 407.7 49 2.1 0.12* 3.3162.89** 30
*P,0.001 and **P,0.0001 vs. 8, 12, and 40 weeks old NTG mice. Mito: mitochondria.
doi:10.1371/journal.pone.0032737.t001
Figure 5. Mitochondria in APP and APP/PS1 mouse brains acquire abnormal shape. A. 2D EM micrograph of mitochondrion with
abnormal shape in Hip tissue of APP mouse 40 weeks of age. B. 3D reconstruction of ten serial sections of consecutive EM micrographs of the same
tissue as in (A). C. 3D reconstruction of mitochondrial structure in Hip tissue of APP/PS1 mouse 24 weeks of age. Note the dramatic elongation of
mitochondrion in APP/PS1 tissue compared to the length and shape of the organelle in the brain of NTG mouse of the same age (D). Scale bar, 1 mm.
doi:10.1371/journal.pone.0032737.g005
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the presence of significant structural abnormalities in APP/PS1 and
APP mice starting at 8 and 12 weeks of age, respectively, and
reaching 20–30% by the age of 40 weeks (Figure 5A–C, Movie S2,
Table 1). Mitochondria acquired abnormal shape, which consisted
of very narrow membranous segments alternated with swollen
round-shaped areas with perturbed cristae resembling ‘‘beads-on-
the-string’’ (Figure 5A–C, Movie S2). Three-dimensional recon-
struction of the EM micrographs demonstrated the age-dependent
increaseinthepresenceoftheseabnormalorganellesintheneuropils
of APP and APP/PS1 mice while only 4 to 5% of similar structures
were found in the brain of PS1 and NTG mice 40 weeks of age
(Table 1). Abnormal mitochondria significantly increased in length
reaching insome cases 26–30 mm (MovieS2). These organelles were
characterized by complete loss of cristae (Figure 6A). Since narrow
segments of abnormal mitochondria are very thin, accurate
estimation of the organelle length in AD mice requires 3D
reconstruction of multiple consecutive micrographs. Therefore, the
estimation of mitochondrial length based on 2D micrographs
(Table 1) may underestimate the extent of organelle elongation in
‘‘beads-on-the-string’’ structures and could convolute the real
increase in mitochondrial length in AD mice with age.
Examination of the ultrastructure of synaptic mitochondria also
revealed the presence of the degenerating organelles with altered
cristae organization (Figure 6B, a–c). Abnormal synaptic mito-
chondria were detected in all three FAD mice starting at 8–12
weeks of age. Thus, changes in organelle structure and
morphology occur in all three FAD mouse models prior to the
onset of memory phenotype and plaque formation [23–25].
Mitochondrial activity is reduced in brain slices from APP,
PS1 and APP/PS1 mice
Next we examined whether mitochondrial structural abnormal-
ities observed in brains of APP, PS1 and APP/PS1 animals were
associated with the inhibition of mitochondrial function. We
adapted the method that allowed measuring mitochondrial mass
and activity in brain slices from control and FAD mice [33,34].
This approach utilizes application of two mitochondrial specific
probes, MitoTracker Green (MTG), which becomes fluorescent
when it accumulates in the mitochondrial lipid environment
regardless of membrane potential, and MitoTracker Orange
(MTO), which measures mitochondrial oxidative activity. MTO
becomes fluorescent only when oxidized with molecular oxygen in
actively respiring mitochondria. The use of both probes avoids
isolation and purification of mitochondria thus preserving cell and
tissue integrity. The ratio between MTO and MTG fluorescence
intensities determines the fraction of active mitochondria in total
organelle content. Brains from NTG, APP, APP/PS1 and PS1
mice 7 months old were cut into 50 mm-thick slices. Each brain
slice was incubated in either buffer alone or in buffer containing
MTG and MTO. Tissue slices were washed and imaged using
LSM 510 confocal microscope. We have found that mitochondria
in all three FAD mice lost oxidative activity comparing to NTG
mice (Figure 6C). The decrease was most prominent in the brains
of APP and APP/PS1 mice (loss of ,50%). The decrease of
oxidative activity in PS1 mice was about 35%. Thus, changes in
mitochondrial ultrastructure observed in FAD mice (Figure 5, 6)
correlate with the loss of mitochondrial function.
Expression of fission and fusion proteins is not altered in
APP, PS1 and APP/PS1 mice
Alterations in mitochondrial dynamics, fission and fusion in
particular, have been implicated in AD progression in humans
Figure 6. Mitochondria in AD mice have altered morphology
and reduced oxidative activity. A. Progressive age-dependent
accumulation of abnormal mitochondria in AD mouse brains with
dramatic loss of cristae integrity. Mitochondrion in APP mouse 45 weeks
of age is shown. Scale bar, 1 mm. B. Abnormal synaptic mitochondria in
APP/PS1 mouse brains were already observed at 8 weeks of age (a–c).
Arrow denotes swollen mitochondria with total loss of inner structure.
(d) Mitochondria in NTG mouse of the same age. Asterisks indicate the
synapses; scale bar, 100 nm. C. Loss of mitochondrial oxidative activity
in relationship to total mitochondrial mass in Hip live brain slices
detected using MTG and MTO. Mitochondria in NTG brain have
extensive colocalization of green (MTG, mitochondrial mass) and red
(MTO, oxidative activity) fluorescence with the ratio of MTG/MTO=0.96.
Mitochondria in PS1, APP and APP/PS1 mouse brains have reduced
oxidative activity as judged by the loss of red fluorescence intensity.
The ratios of MTG/MTO were estimated to be: 0.8 (PS1), 0.6 (APP), and
0.5 (APP/PS1). Images were acquired using LSM 510 with 406 lens.
Scale bar, 10 mm.
doi:10.1371/journal.pone.0032737.g006
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mitochondrial morphology observed in the brains of FAD mice
were related to the altered expression of key proteins involved in
mitochondrial dynamics. First, we investigated whether levels of
expression of mitochondrial fusion (Opa1, Mfn1, and Mfn2) and
fission proteins (Drp1 and Fis1) were altered in the whole brain
tissue extracts from NTG, APP/PS1 and PS1 mice 40 weeks of age
(Figure 7A). As a control, we used the essential component of the
inner mitochondrial membrane translocase complex Tim 23.
Immunoblot analysis revealed no changes in the levels of expression
of all six proteins. No significant differences in overall mitochondrial
content were noted between samples from APP/PS1, PS1 and
NTG mice evident by the constant expression levels of Tim 23, a
mitochondrial marker. We next determined levels of expression of
fission/fusion proteins in the different brain regions in APP and
NTG mice 45 weeks of age (Figure 7B). Immunoblot analysis of
protein extracts from Hip, Ctx and cerebellum (Cer) also revealed
no changes in the expression levels of all proteins examined
(Figure 7B). Our data suggest that changes in mitochondrial
morphology observed in APP and APP/PS1 mice (Figure 5, 6) were
not caused by altered expression of mitochondrial fission or fusion
proteins.
APP, PS1 and APP/PS1 mice have distinct gender- and
mutation- related changes in metabolomic profiles in
brain tissue
We have demonstrated that mitochondrial trafficking, distribu-
tion, morphology and function are affected in brain tissue from all
three FAD mice prior to the onset of cognitive decline or plaque
formation. However, the development of mitochondrial abnor-
malities was different in each FAD mouse model. Thus, inhibition
of mitochondrial trafficking was observed in embryonic neurons
from PS1 and APP/PS1 mice, but not in APP mice. Similarly,
changes in mitochondrial morphology were prominent in APP and
APP/PS1, but not in PS1 mice. To determine how particular FAD
mutation affects metabolic pathways involved in mitochondrial
function and energy metabolism, we analyzed metabolomic
profiles in the Hip tissue of PS1, APP and APP/PS1 mice
(Figures 8, 9, Table 2). Tissue from 36 week old APP and PS1
mice and 16 week old APP/PS1 mice was analyzed and compared
to age- and gender-matched NTG littermates. The selection of
mouse age for metabolomics was determined by differences
between the onset of memory phenotype and amyloid plaques in
FAD mice. Data analyses using PLS-DA revealed that PS1, APP
and APP/PS1 mice have metabolomic phenotypes that are
distinct from NTG littermates and also from each other
(Figure 8A). Separate analysis comparing metabolomic signatures
in APP/PS1 mice revealed significant gender-related differences
(Figure 8B). Thus, NTG female and male mice have very similar
metabolomic profiles, while profiles of APP/PS1 female and male
mice differed significantly (Figure 8B). Additionally, the extent of
alterations in metabolic signatures was greater in female APP/PS1
mice compared to male mice (Figure 8B, arrows between NTG
and APP/PS1 males and NTG and APP/PS1 females).
Since gender was found to have a significant impact on
metabolomic profiles, we focused on the comparison of the
changes in metabolites specifically in the brain tissue of age-
matched female APP, APP/PS1, PS1 mice and NTG littermates
(Figure 9, Table 2). Metabolites in the separate pair comparison
revealed presence of characteristic signatures of mitochondrial
toxicity with altered tissue levels of energy metabolites ATP, ADP,
AMP, nicotinamide adenine dinucleotide (NAD), adenosine,
fumaric acid, adenine, creatine and b-alanine (Figure 9, middle
panels). Increased levels of adenosine, AMP and fumaric acid and
decreased levels of N-acetyl aspartate (NAA) strongly suggest
presence of mitochondrial stress and energetic dysfunction.
Metabolic pathway analyses revealed that in all three FAD mouse
models there are significant alterations in the levels of metabolites
involved in energy metabolism including nucleotide metabolism,
mitochondrial Krebs cycle, energy transfer, carbohydrate, neuro-
transmitter and amino acid metabolic pathways (Figure 9, right
panels). However, along with the pathways equally affected in all
three FAD mouse models, we identified metabolic pathways and
metabolites that were specific to the mutation. Thus, alteration in
neurotransmitter metabolism and energy transfer pathway was
affected to a greater extent in APP and PS1 mice (Figure 9, right
panels). Synergistic effect of both mutations in APP/PS1 mice
resulted in significantly stronger alterations in glycolytic pathway
that involved Krebs cycle, and neurotransmitter and amino acid
metabolism (Figure 9, right panels, Table 2). Metabolites that were
uniquely affected in APP mice included panthotenic acid while
threonate and ethanolamine were uniquely affected in APP/PS1
mice (Table 2). Moreover, in all three FAD mouse models we also
found changes in the levels of NAA, myo-Inositol and creatinine
Figure 7. Expression of mitochondrial fusion and fission
proteins is not altered in brain tissue from AD mice.
Representative immunoblot (A) revealed no differences in expression
of fusion and fission proteins in brain tissue from 12 months old APP/
PS1, PS1 and NTG mice. B. No changes in expression of fission/fusion
proteins were found in different brain regions (hippocampus, Hip,
cortex, Ctx, and cerebellum, Cer) in APP mouse 13 months old
compared to NTG mouse of the same age. Each sample was loaded
twice with second sample having 26concentration.
doi:10.1371/journal.pone.0032737.g007
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the diagnosis of mild cognitive impairment and AD in humans
[37]. Our data demonstrate that mitochondrial dysfunction is
present early in development of AD in all three FAD mouse
models regardless of the origin of the mutation. Moreover,
metabolomic profiling could discriminate between the effect of
gender and specific mutations on the metabolic pathways involved
in mitochondrial dysfunction and energy failure.
Discussion
Identification of the early molecular mechanisms underlying
AD is of great importance in order to develop efficient methods for
diagnosis and therapeutic intervention. Growing evidence suggests
that mitochondrial dysfunction occurs prior to the onset of
memory phenotype and plaque formation and is an important
factor that modulates AD pathophysiology [38,39]. Indeed,
mitochondrial bioenergetics deficits precede the onset of AD
symptoms in multiple AD animal models [40,41]. In humans,
regional glucose hypometabolism is detected many years before
the disease onset in PS1 mutation carriers [42]. Biochemical
studies demonstrate alterations in the activity of mitochondrial
enzymes involved in Krebs cycle and electron transport chains
in the post mortem AD brains [4,43]. Recently, defects in
mitochondrial morphology, distribution and dynamics have been
found in the human AD brain tissue and in cellular and animal
models of AD [20,22,36,44–46]. However, the molecular mecha-
nisms underlying mitochondrial dysfunction in AD remain elusive.
Part of the problem relates to the lack of a model organism that
recapitulates all aspects and complexity of AD, and specific
limitations of the multiple animal models currently used in research
laboratories.
We utilized three FAD mouse models to determine whether
mitochondrial dysfunction was implicated in the early stages of AD
regardless of the origin of FAD mutation, which would validate
mitochondria as the target for early therapeutic intervention. We
have found that inhibition of axonal trafficking of mitochondria
was among the earliest abnormalities already detected in
embryonic neurons from PS1 and APP/PS1 mice months before
the onset of memory phenotype or formation of amyloid deposits
Figure 8. Brain tissue of APP, PS1, and APP/PS1 mice has distinct metabolomic profiles compared to NTG mice. A. PLS-DA score plot
showing distinct metabolomic profiles of Hip brain tissue from PS1, APP and APP/PS1 mice compared to NTG mice. B. PLS-DA score plot
demonstrating a significant gender effect on metabolomic profiles in APP/PS1 mice. Metabolomic alterations associated with mitochondrial
dysfunction were more pronounced in female than in male APP/PS1 mice. Note significant differences in metabolomic profiles between APP/PS1
males and females and much smaller variation between NTG males and females. Each group included 3 mice 16 week of age.
doi:10.1371/journal.pone.0032737.g008
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peptides on mitochondrial motility [18,19,31,47,48]. However,
comparison of Ab levels in the Hip tissue of newborn FAD mice
with and without trafficking defect suggests that inhibition of
mitochondrial trafficking in PS1 mice occurs through Ab-
independent mechanism. Indeed, it has been shown that mutant
PS1 could directly affect axonal machinery by modulating the
activity of glycogen synthase kinase-3b (GSK-3b) that controls the
release of kinesin motor protein from the cargo [17,21,49]. In
addition, PS1 mutations may affect mitochondrial trafficking by
altering calcium homeostasis [50,51]. Elevated calcium levels
caused by PS1 mutations lead to an increased calcium uptake by
mitochondria resulting in trafficking inhibition [15,52]. However,
the exacerbated trafficking phenotype observed in double mutant
APP/PS1 mice where levels of Ab were significantly elevated in Hip
and Ctx tissue of newborn mice suggests synergistic effect of each
mutation and implication of Ab-dependent and independent
mechanisms. Our data also support recent observations suggesting
that Ab oligomers represent toxic species that disrupt axonal
trafficking [8,53,54]. The extent of trafficking inhibition in APP/
PS1 mice correlated with significantly elevated levels of oligomeric
Ab in the Hip brain tissue of the newborn mice. Surprisingly,
mitochondrial trafficking was not altered in embryonic neurons
from APP mice where levels of Ab were higher that in PS1 mice.
However, since we have found that axonal trafficking of other cargo
was inhibited in APP neurons, it is possible that levels of Ab in
embryonic neurons from APP mice did not yet reach the threshold
required to cause detectable trafficking inhibition of mitochondria.
This is supported by the observations that Ab levels increase with
time in the brain of the APP mice [23,28], and that axonal
trafficking inhibition of cargo other than mitochondria was detected
in APP mice in vitro and in vivo [55,56]. It remains to be determined
whether inhibition of mitochondrial motility occurs in APP mice
and whether that contributes to mitochondrial dysfunction.
Another important function of mitochondria in the cell includes
buffering of intracellular cytosolic Ca
2+ [57]. Decreased age-related
Ca
2+ buffering capacity and deregulation of Ca
2+ homeostasis can
potentiate excitotoxicity, a phenomenon intimately associated with
neurodegeneration [30,57,58]. Positioning and ability of mitochon-
dria to move is important for proper Ca
2+ buffering [59,60]. We
have found that embryonic neurons from all FAD mice exhibited a
higher level of cell death in response to the NMDA treatment.
However, neurons from PS1 and APP/PS1 mice were affected to
the higher extent suggesting that altered mitochondrial motility
predisposes neurons to excitotoxic cell death.
Analysis of the pattern of mitochondrial motion also revealed a
mutation-specific impact. Thus, only in PS1 neurons mitochondria
covered significantly shorter distances between stops. This is
Figure 9. Comparison of individualized metabolomic profiles and affected metabolic pathways in FAD mouse models. A, C and E.
PLS-DA score plots showing distinct metabolomic profiles of PS1 (A), APP (B) and APP/PS1 (C) female mice compared to NTG littermates. A, B and C,
middle panels. Panels of specific biomarkers as a plot of variable importance in the projection (VIP) indicating the 15 most significant metabolites in
discriminating between metabolomic profiles of NTG and Tg groups in the PLS-DA model. A, B and C, right panels. Metabolic pathways
specifically affected in each FAD mouse model. APP and PS1 mice were 36 weeks old, APP/PS1 – 16 weeks old.
doi:10.1371/journal.pone.0032737.g009
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increased phosphorylation of cytoskeletal proteins observed in
FAD-linked PS1 mice [21,61,62]. However, changes in mitochon-
drial length and distribution were prominent in all three FAD
mouse models and already observed in embryonic neurons. The
significant increase in mitochondrial length in APP, PS1 and APP/
PS1 mice correlates with the reduced numbers of organelles in
neuropils. The dynamic relationship between the number of mito-
chondria in neuropils and mitochondrial length may represent the
attempt to maintain constant or increased mitochondrial mass to
ensure adequate energy supply. We have also observed the
dramatic change in the shape of mitochondria in the brain of APP
and APP/PS1 mice. To our knowledge, this is the first report of
such structures acquired by mitochondria in AD animal models.
Interestingly, the dramatic changes in mitochondrial shape
observed only in APP and APP/PS1 mice can’t be explained by
altered expression of fission and fusions proteins shown to be
implicated in AD before [9,63,64]. The mechanism involved in
the formation of such structures remains to be determined.
Examination oftheultrastructureofsynapticmitochondriarevealed
the increased presence of organelles with altered morphology in all
FAD mice starting at 8 weeks of age.
Not surprisingly, alterations in mitochondrial distribution and
morphology coincide with the loss of mitochondrial oxidative
activity in the brainof all three FADmouse models, whichpreceded
the onset of amyloid plaque formation and memory phenotype
[23,27,65,66]. Taken together, our data suggest that individual
FAD mutations facilitate loss of mitochondrial motility, alterations
in organelle distribution, loss of morphology and function, which
are the early events associated with AD progression.
Application of metabolomics, a global biochemical approach to
reveal disease-specific signature of metabolic perturbations, con-
firmed that mitochondrial function and cellular energy metabolism
were altered in all three FAD mouse models. Metabolomic
signature of mitochondrial dysfunction was detected in APP/PS1
mice at 16 weeks and in PS1 and APP mice at 8 months of age prior
Table 2. Relative changes of 30 most important metabolites in APP, PS1 and APP/PS1 transgenic mice compared to aged and
gender matched NTG littermates.
PS1 mice FC VIP p APP mice FC VIP p APP/PS1 mice FC VIP p
ADP 20.56 1.59 0.003 NAA 23.76 1.83 0.004 Threonic acid 1.08 1.59 0.003
NAD 20.49 1.53 0.006 Myo-inositol 20.50 1.76 0.006 Ethanolamine 1.67 1.52 0.012
ATP 20.50 1.50 0.011 Pantothenic acid 21.74 1.71 0.011 Alanine 2.22 1.51 0.048
Pi 20.92 1.49 0.016 Pi 20.93 1.69 0.014 Mannitol 1.22 1.48 0.024
Fumaric acid 20.88 1.47 0.014 Adenosine 0.60 1.69 0.031 Glycerol 3-P 1.46 1.46 0.020
Myo-inositol 20.55 1.46 0.016 AMP 1.60 1.58 0.041 Pyroglutamic acid 0.54 1.44 0.026
Malonic acid 20.50 1.42 0.024 Threose 20.16 1.54 0.047 NAA 0.65 1.41 0.032
Lysine 20.65 1.41 0.030 Creatinine 20.78 1.51 0.054 Creatinine 0.62 1.37 0.062
GDP 20.41 1.34 0.044 IMP 20.76 1.43 0.078 Lactic acid 0.50 1.37 0.044
Threose 20.81 1.32 0.052 Malonic acid 20.29 1.40 0.088 Succinic acid 0.88 1.35 0.054
Glycerol 20.83 1.30 0.082 ATP 20.63 1.33 0.114 Methylglutamate 0.69 1.33 0.143
GTP 20.35 1.29 0.061 Glycerol 20.42 1.32 0.123 NAD 0.22 1.33 0.057
NAA 20.42 1.28 0.067 Adenine 0.50 1.28 0.135 Adenosine 1.39 1.32 0.063
Glutamic acid 20.96 1.28 0.072 Fumaric acid 0.21 1.27 0.412 Adenine 0.70 1.30 0.065
GMP 20.30 1.27 0.078 Inosine 20.61 1.27 0.138 Citric acid 0.69 1.28 0.073
Malic acid 20.55 1.27 0.076 Citric acid 20.31 1.25 0.152 Inosine 1.65 1.24 0.090
Creatinine 20.73 1.25 0.074 ADP 20.46 1.23 0.181 Glycine 1.75 1.23 0.095
Citric acid 21.64 1.21 0.110 Beta- alanine 0.28 1.20 0.175 Aspartic acid 1.42 1.23 0.099
4-guanidinobutyrate 20.58 1.18 0.114 Lactic acid 20.28 1.12 0.216 Glyceric acid 1.33 1.20 0.107
AMP 20.39 1.16 0.115 Nicotinic acid 0.79 1.09 0.318 Glutamine 2.21 1.18 0.155
IMP 20.28 1.16 0.158 Lyxose 20.25 1.06 0.299 Lysine 2.25 1.16 0.122
Beta- alanine 20.57 1.16 0.124 Uracil 20.28 1.00 0.378 THBA 0.95 1.14 0.181
Palmitic acid 0.43 1.15 0.134 Pyrophosphate 0.48 0.97 0.356 Uracil 0.54 1.12 0.143
Urea 1.28 1.13 0.355 GDP/NADP 20.21 0.96 0.413 4-Aminobutyric acid 1.94 1.09 0.165
Cholesterol 22.57 1.05 0.258 O-phosphocolamine 0.30 0.96 0.395 Cytidine/Hypoxanth 0.81 1.02 0.195
Succinic acid 20.58 1.04 0.179 Methylglutamate 20.39 0.92 0.325 Glycolic acid 0.82 1.02 0.205
Stearic acid 0.46 1.03 0.194 Glutamic acid 20.35 0.91 0.359 Serine 2.43 1.01 0.258
Glycolic acid 20.26 1.00 0.201 GTP 20.25 0.89 0.413 IMP 0.52 1.01 0.234
Adenosine 0.42 0.99 0.200 Stearic acid 0.55 0.89 0.341 Uridine 0.94 0.97 0.228
Uracil 20.50 0.98 0.224 Iminodiacetic acid 0.60 0.89 0.410 GMP 0.53 0.95 0.246
For each group, the relative values of each metabolite (mean6SD) are the average obtained from three mice. The average basal metabolite values of NTG group were
arbitrarily set at 1 for each group. The value of fold change (FC, log2 of fold change) for each metabolite is relative to the value in aged and gender matched NTG mice.
Metabolites were selected based on VIP values; p values were estimated using Student’s t-test.
doi:10.1371/journal.pone.0032737.t002
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Data analysis using PLS-DA showed distinct metabolomic pheno-
types in brains of PS1, APP and APP/PS1 mice. Metabolomic
signatures of 15 most important metabolites in group separation
included molecules linked to mitochondria and energy metabolism,
such as inorganic phosphates (Pi), creatinine, NAA, AMP,
adenosine, malonic acid, IMP, adenine, b-alanine, lactic acid,
ATP, and glycerol. Metabolic pathway analysis revealed that in all
three FAD mouse models there are significant alterations in the
levels of metabolites involved in energy metabolism including
nucleotide metabolism, mitochondrial Krebs cycle, carbohydrate,
and amino acid metabolic pathways, which is in agreement with
studies conducted in patients and AD mice [67–70]. However,
along with the pathways equally affected in all three FAD mouse
models,we identified metabolic pathways and metabolites that were
affected differentially. Thus, alteration in lipid metabolism and
energy transfer pathway was specifically observed in APP and PS1
mice, while alterations in glycolytic pathway were prevalent in
APP/PS1 mice. Also, mitochondrial Krebs cycle and amino acid
metabolism were affected to a greater extent in APP/PS1 mice
compared toPS1and APPmiceindicating synergistic effectsofboth
mutations. We have also found that APP/PS1 mice display marked
gender differences with female mice having greater metabolic
disturbances similar to that observed in human AD patients [71].
Discrimination analysis of individualized metabolomic profiles
between single and double mutant FAD mice in simultaneous
comparison identified panels of metabolic biomarkers that have
predictive power for distinction among three groups, i.e. NTG,
PS1 and APP/PS1 and between NTG, APP and APP/PS1 with
different degree of AD progression. Metabolites that were uniquely
affected in APP mice included panthotenic acid while threonate
and ethanolamine were uniquely affected in APP/PS1 mice. Thus,
metabolomic signatures of PS1, APP, and APP/PS1 mice indicate
individual differences and common metabolic traits in disease
development and progression. In all FAD mice, levels of NAA,
allo-Inositol and creatinine, molecules that are currently used for
the diagnosis of mild cognitive impairment and AD in humans
using
1H MRI [37], were also affected indicating similarity with
human AD. Taken together, our data demonstrate the presence of
distinctive changes in mitochondrial motility, dynamics and
morphology that correlate with the changes in the levels of
metabolites reflecting altered energy metabolism and mitochon-
drial dysfunction in brain of FAD mice. These changes are
mutation specific and could be used for an early diagnosis and
monitoring the disease progression. Thus, AD could be viewed as
mitochondrial movement disorder with evolving energetic deficit
epitomized in the panel of metabolomic biomarkers.
Materials and Methods
Animals
Three transgenic mouse lines carrying mutations associated
with FAD were used in the study. The APP mice were
heterozygous transgenic mice (C57B6/SJL, I.D. No. Tg2576) that
expressed mutant human APP695 containing a double mutation
(K670N, M671L) [23]. The PS1 mice were homozygous
transgenic mice (Swiss Webster/B6D2; I.D. No. M146L) that
express mutant human PS1 containing a single mutation (M146L)
[26]. The double transgenic mice, APP/PS1, were produced in
house by crossbreeding of homozygous PS1 and heterozygous APP
mice [28]. The animals were genotyped for the expression of both
transgenes by a PCR method using a sample of mouse tail DNA.
Littermates that did not carry transgenes were used as non-
transgenic control (NTG). All procedures were performed using
humane and ethical protocols approved by the Mayo Clinical
Institutional Animal Care and Use Committee, in accordance with
the National Institute of Health’s Guide for the Care and Use of
Laboratory Animals.
Preparation of neuronal cultures
Preparation and culturing of primary hippocampal (Hip) and
cortical (Ctx) neurons were performed as described previously
[72]. Briefly, mice were anesthetized with isoflurane on gestational
day 17–18 and fetuses were rapidly removed. Fetal brains were
extracted and placed in sterile HEPES- buffered saline (HBS)
(pH 7.3). The hippocampi were dissected from each embryo and
treated separately. Tissue from each embryo was collected for
genotype identification using PCR. Hippocampi were placed in
1 mg/mL papain (Warthington, NJ) in HBS for 20 min at 37uC.
After two washes in HBS, the dissociated tissue was triturated in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
Ham’s F12 with glutamine (Gibco/BRL, Grand Island, NY), 10%
heat inactivated fetal calf serum (Hyclone Laboratories Logan,
UT) and 16 pen/strep antibiotic mixture. Cells were counted,
diluted to 3610
5 cells/mL, and 2 ml of this stock was placed in
each well of a 6-well dish containing glass coverslips coated with
poly-L-ornithine (1 mg/2 mL sterile borate buffer, pH 8.4). Plated
cells were maintained in an incubator with 5% CO2 at 37uC. After
72 h in culture, serum-containing medium was replaced with a
serum-free Neurobasal-based medium (without glutamine, Gibco/
BRL, Grand Island, NY) containing 16pen/strep antibiotic
mixture and 16B27 supplement (Gibco/BRL, Grand Island,
NY). Quantification of neurons and glial cells using specific
antibody staining (GFAP for astrocytes, AB5804, Millipore, and
neuron specific bIII-tubulin, ab18207, Abcam) demonstrates that
neurons represent 95% of cells present on the coverslip. In cases
where experiments required especially pure neuronal cultures,
cells were treated with cytosine b-D-arabinofuranoside (Ara-C,
Sigma, MO) to a final concentration of 2 mM after 3 and 5 days in
culture to suppress proliferation of the glial cells. Such conditions
resulted in obtaining fully developed pure Hip neurons exhibiting
synaptic activity as judged by staining with synapsin antibody (ab8,
Abcam).
Real time imaging of axonal trafficking in live neurons
Experiments with mitochondrial trafficking were performed as
described previously [29]. Briefly, neurons after 7 days in culture
(DIC) were treated for 15 min with TMRM (Molecular Probes,
Eugene, OR) (final concentration 50 nM). TMRM was washed
away with fresh F-12K medium prior to imaging. The
experiments were performed using confocal microscope LSM
510 (Carl Zeiss Inc, Germany) with a Plan-Apochromat 1006(1.4
na) oil objective. Cells were incubated at 37uC during the time of
recording. All recordings were started five minutes after the
coverslip was placed on the microscopic stage to allow equilibra-
tion of the sample. Laser was set up to 543 nm for excitation;
emission was collected at 585 nm and greater. Axons were selected
based on the lack of branching through the whole length. In some
cases, verification of neurite identity was made by applying specific
antibodies to distinguish dendrites from the axons. A total of 600
images were recorded per cell. Images were taken every 1 sec at
highest scan speed (0.9 sec) for 10 min. Three different cells were
imaged from one coverslip. Movies were analyzed using LSM 510
software that allowed animation of 600 images into a ‘‘movie’’.
Along with the channel that recorded fluorescence images of
moving mitochondria, we recorded axonal movement of the
vesicles that were clearly visible in the bright field and were
not stained with TMRM. For analysis of axonal trafficking of
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the first frame of the movie to the last. We recorded time and
distance that particular mitochondrion traveled in axons, and
calculated velocities in anterograde and retrograde directions. We
also analyzed the pattern of motion for each mitochondrion. Thus,
we estimated whether Mito moved in smooth or stop-and–go
mode, what the distances were that Mito covered between stops,
and how often did it stop and change direction. We also estimated
the fraction of time each Mito spent in motion or stationary state
during the time of observation. Data were analyzed for each
genotype. At least 22 neurons from 3–5 independent platings were
analyzed for each genotype. In some cases, axonal trafficking was
analyzed using analytical software Analyze where each Mito was
traced through all 600 frames producing kymographs (Figure 1D).
NMDA treatment
Primary Hip or Ctx neurons (E17) from WT mice were plated
as described above. Six days after plating, neurons were switched
to DMEM medium without Ca
2+ and Mg
2+ ions. Cells were
treated with different doses of NMDA (1–80 mM) for 5 min. Cells
were washed 36 with (DMEM without Ca
2+,M g
2+) media and
returned to the incubator for 24 hrs. Cells were scraped and spun
down; medium was aspirated; and cells were re-suspended in
100 ml of fresh DMEM medium. Cell viability was examined using
trypan blue staining. Experiments were repeated four times in
triplicates with different neuronal platings.
Immunohistochemistry
The brains from one-day old neonatal APP, PS1, APP/PS1 and
NTG mice were immersion fixed with neutral-buffered 10%
formalin. Twenty-five micron sections were cut on a cryostat and
thaw-mounted on gelatin coated slides. Three sets of adjacent
sections from each mouse underwent immunohistochemistry with
two different anti-fibrillar Ab mouse monoclonal antibodies (4G8,
1:1000, SIG-39220; 6E10, 1:1000, SIG-39320; Covance Research
Products, Berkeley, CA) and an anti-oligomeric Ab rabbit
polyclonal antibody (A11, 1:5000, AB9234; Chemicon/Millipore,
Temecula, CA) using standard ABC immunoperoxidase methods
(mouse monoclonal - Vector M.O.M. Peroxidase Kit, PK-2200;
rabbit polyclonal – Vectastain Elite ABC, PK-6101; Vector
Laboratories, Burlingame, CA). The sections were dried overnight
in an oven at 37uC. The sections were then rehydrated with 0.3%
Triton X in phosphate-buffered saline (PBST). Endogenous
peroxidase activity in the sections was quenched by reacting with
0.5% H2O2 in PBST for 30 min. The sections were blocked with
M.O.M. blocking solution (mouse monoclonal) or 10% goat serum
(rabbit polyclonal) in PBST for 60 min. The sections were
incubated with the primary antibody at the designated dilution
in 0.1% BSA/0.3% Triton-X/PBS overnight at 4uC. The second
day, sections were rinsed twice with PBST for 5 min each and
then incubated with the appropriate biotinylated secondary
antibody at a dilution of 1:250 for 60 min. After rinsing twice in
PBST for 5 min each, sections were incubated with the ABC
reagent for 60 min and then rinsed twice in PBS (minus 0.3%
Triton X-100) for 5 min each. Sections were reacted with
peroxidase substrate (VIP; SK-4600; Vector Laboratories) for an
equal amount of time and were then rinsed three times in tap
water for 5 min each. Sections were then dehydrated with
successive changes of ethanol and xylene and coverslipped.
Densitometry measurements
Using grayscale images with black equal to 0 and white equal to
255, the mean gray level intensity was measured in three
100 mm6100 mm reticles in cortex and CA1 hippocampal subfield
of neonatal NTG, PS1, APP, and APP/PS1 mouse brain. All
histochemical conditions, as well as microscope and camera
settings were kept constant between all brain sections. The
intensity values were normalized against the background intensity
of the bare glass slide adjacent to the tissue sections. The
normalized values are expressed as ratios with lower values
indicating darker, more intense antibody staining and therefore
higher levels of Ab. The normalized intensity ratios for 4G8
immunostaining of Ab for the cortex and CA1 of the NTG mouse
brain were 0.9560.01 (mean 6 SEM) and 0.9460.01, respec-
tively. The normalized intensity ratios for the cortex and CA1 of
the PS1 mouse brain were 0.9360.01 and 0.9360.00, respective-
ly. The normalized intensity ratios for the cortex and CA1 of the
APP mouse brain were 0.9260.00 and 0.8960.00, respectively.
The normalized intensity ratios for the cortex and CA1 of the
APP-PS1 mouse brain were 0.8660.01 and 0.7560.01, respec-
tively. The normalized intensity ratios for A11 immunostaining of
oligomeric Ab for the cortex and CA1 of the NTG mouse brain
were 0.9360.01 (mean 6 SEM) and 0.9360.01, respectively. The
normalized intensity ratios for the cortex and CA1 of the PS1
mouse brain were 0.7760.00 and 0.8160.00, respectively. The
normalized intensity ratios for the cortex and CA1 of the APP
mouse brain were 0.8060.01 and 0.8160.00, respectively. The
normalized intensity ratios for the cortex and CA1 of the APP-PS1
mouse brain were 0.7060.00 and 0.6860.00, respectively.
Western blot analysis
Expression of mitochondrial fission and fusion proteins was
detected using the following antibodies: rabbit polyclonal Opa1
(1:1000, Novus Biologicals), mouse monoclonal Opa1 (1:1000, BD
Transduction Laboratories), mouse monoclonal Dlp1 (1:1000, BD
Transduction Laboratories), chicken Mfn1 (1:1000, Novus Bio-
logicals), rabbit polyclonal Mfn2 (1:1000, Sigma-Aldrich), mouse
monoclonal Mfn2 (1:1000, Abnova), rabbit polyclonal Fis1 (1:500,
Alexis Biochemicals), and mouse monoclonal Tim23 (1:1000, BD
transduction Laboratories). Tissue extracts were prepared from
either the whole brain or from dissected cerebellum, cortex and
hippocampus from APP/PS1, PS1, APP and NTG mice 11–12
months old. Tissue was homogenized and lysed using 16 RIPA
Buffer plus inhibitors. 20 and 40 mg of protein from the same
sample was loaded in every well. Proteins were separated by SDS-
PAGE using 4–20% Criterion Tris-HCl gels (Bio-Rad). Proteins
were visualized by fluorophores conjugated with secondary
antibodies (ZyMaxTM Goat Anti-Rabbit IgG (H+L) CyTM 5
conjugate and/or Alexa Fluor 488 goat anti-mouse IgG (H+L),
Invitrogen) and analyzed using a PharosFX Plus Molecular
Imager (Bio-Rad).
Estimation of mitochondrial mass and activity
NTG, APP, APP/PS1 and PS1 mice 7 months old were
sacrificed by decapitation, brains were quickly removed and
placed in ice-cold Krebs-Ringer Bicarbonate Buffer (KRB)
pH=7.3 [73]. Brains were embedded in 2.5% agar and cut
coronally by Vibratome into 50 mm-thick slices. Each brain slice
was incubated for 15 min at RT in either KRB alone or KRB
containing MitoTracker Green (MTG) and MitoTracker Orange
(MTO) (both from Molecular Probes) as described in [34]. Tissue
slices were washed in KRB and imaged using LSM 510 confocal
microscope (406lens; MTG, ex 490/em 516 nm; MTO, ex 551/
em 576 nm). Estimation of MTG and MTO fluorescence
intensities was done using LSM Physiology software. The ratios
between MTG and MTO fluorescence were taken as a measure of
mitochondrial activity. At least five images for each genotype were
taken into analysis.
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For conventional electron microscopy, animals were perfused
with 4% paraformaldehyde, brains were removed and post-fixed
in Trump’s solution overnight. Next day, Hip (CA1 region) was
dissected from each brain and subjected to EM staining. CA1 Hip
tissue was incubated in 1% osmium tetroxide, dehydrated in a
graded series of ethanol and embedded in Quetol 651 (Ted Pella,
Inc). Thin sections (0.09–0.1 mm) were cut parallel to the ventral
surface using a diamond knife (Diatome US) and an Ultracut E
microtome (Reichert-Jung, Wien, Austria). Sections were collected
on copper grids, post-stained with lead citrate and viewed at
,80 kV with a JEOL 1400 transmission electron microscope
(JEOL USA). Three to five randomly selected micrographs per
each age and genotype were analyzed by blinded investigator. The
following parameters were estimated: the number of mitochondria
with abnormal shape, the number of mitochondria per neuropil,
neuropil length, number of mitochondria per neuropil length, and
the average length of mitochondria. The following mice were used
for the EM examination: APP/PS1, PS1, APP and NTG of 8, 12,
24, 30, 33, 40, 45 and 64 weeks of age.
Sample preparation and metabolomic analysis
Metabolic signatures were generated in three female NTG, PS1
and APP mice 36 weeks old, and in the groups of three female and
three male NTG and APP/PS1 mice 16 weeks old. Adult mice
were sacrificed; brains were rapidly removed; Hip tissue was
dissected and flash-frozen in liquid nitrogen. Tissue was pulverized
under liquid N2 and extracted in a solution containing 0.6 M
HClO4 and 1 mM EDTA [74,75]. Extracts were neutralized with
2M KHCO3 and used for metabolomic analysis. For gas-
chromatograph/mass-spectrometer (GC-MS) analysis, 100 mLo f
extract was transferred into Eppendorf tube and spiked with 5 mL
internal standard (IS), myristic-d27 acid, (1 mg/mL) at ambient
temperature. After gently vortexing, samples were completely
dried in a SpeedVac concentrator. The samples were subsequently
methoximated using 20 mL of a 20 mg/mL solution of methox-
yamine hydrochloride in pyridine at 30uC for 90 min and then
derivatized using 80 mL of N-methyl- N-trimethylsilyltrifluoroace-
tamide with 1% trimethylchlorosilane (MSTFA+1% TMCS,
Pierce) at 37uC for 30 min [76]. Metabolite levels were
determined using GC-MS (Hewlett-Packard, HP 5980B) with
DB5-MS column and HPLC (Hewlett-Packard, series 1100) with
Mono QTM column (GE Healthcare Bio-Sciences AB) using a
triethylamine bicarbonate elution buffer (pH 8.8), and a reverse
phase C-18 column using a phosphate buffer, tetrabutylammo-
nium sulfate and methanol mixture [77–79]. GC-MS spectra were
deconvoluted using AMDIS software, after that SpectConnect
software was used to create metabolite peaks matrix [80,81]. The
Agilent Fiehn GC/MS Metabolomics RTL Library was used for
metabolite identifications. The matrix data were exported to
SIMCA-P+ software (v12.0, Umetrics, Umea, Sweden) for
multivariate data analysis. Unsupervised principal component
analysis was run to detect any innate trends and potential outliers
within the data. Supervised partial least squares discriminant
analysis (PLS-DA) was performed to obtain additional information
on differences in the metabolite composition of groups. PLS-DA
models were calculated with unit variance scaling, and the results
were visualized in the form of score plots to show the group
clusters. The VIP (variable importance in the projection) values
and regression coefficients were calculated to identify the most
important molecular variables for the clustering of specific groups.
The PLS-DA model was validated by comparison to the
classification statistics of models generated after random permu-
tations of the class matrix [82,83].
Statistical Analysis
Statistical analyses of means for more than two groups were
performed using one-way analysis of variance (ANOVA) with the
categories of genotype and age as independent factors followed by
the Newman-Keuls post-hoc test for multiple comparison. For
analyses of means involving only two groups with a sample size
n,30, the F-test was used to determine if the variances between the
two groups were significantly different. For samples with a
significant difference in variance, the Welch’s t test was applied.
Student’s t test was applied for the samples with an insignificant
difference in variance of where n$30. The null hypothesis was
rejected at the 0.05 level. All statistical computations were carried
out using Prism (Graphpad Software). Results for the vesicular
motility and length are expressed as the mean 6 S.D. For
multivariate data analysis, unsupervised principal component
analysis (PCA) and supervised PLS-DA were done using SIMCA-
P+ software (v12.0, Umetrics, Umea, Sweden). The details of data
analysis implemented in metabolomic study are described above.
Supporting Information
Movie S1 Axonal trafficking of mitochondria in primary
neuron from NTG mouse. Visualization of mitochondria in
E17Hipneuronwas done usingTMRM.600frames were acquired
by imaging the axon every second using LSM 510 confocal
microscope. Imaging was done focusing on the axon with the cell
body located at the top of the image. Resulting movie was analyzed
using Analyze, a comprehensive multidimensional medical image
processing, visualization and analysis software package developed
by the Biomedical Imaging Resource of the Mayo Clinic [84]. By
treating the microscope image sequence as a spatial stack of cross-
sectional images, the volume rendering algorithms in Analyze
produce a 3D digital kymograph, allowing the motion of multiple
organelles over a period of time to be visualized in a single static 2D
image. Final kympgraph allows tracing each mitochondrion
through all 600 frames to generate a final profile of movement.
(MPG)
Movie S2 Animated 3D reconstruction of mitochondrial
structure in Hip tissue of APP/PS1 mouse 24 weeks of
age. For 3D reconstruction of the mitochondrial structure, the
grayscale of the individual EM section images was first inverted so
that the organelle became bright objects. The inverted images
were then sequentially co registered using the Normalized Mutual
Information 2D registration program in Analyze [84]. This is an
automated procedure that aligns similar images based on the
statistical distribution of paired pixels compared to the distribution
in either image alone. The inverted, co-registered stack was then
rendered using Maximum Intensity Projection. Each pixel in the
rendered image represents the brightest voxel in a ray from the
viewers’ eye through the entire stack of sections.
(MPG)
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